Zavesca (miglustat)
- Region
- 🇪🇺 EU
- Active substance
- miglustat
- Company
- Advanz Pharma Limited
- Status
- Authorised
- Therapeutic area
- Gaucher Disease; Niemann-Pick Diseases
- EU approval
- Wed 20 Nov 2002
- Application
- EMEA/H/C/000435
- ATC
- A16AX06
- Official record
- www.ema.europa.eu
Indication
Zavesca is indicated for the oral treatment of adult patients with mild to moderate type-1 Gaucher disease. Zavesca may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable. Zavesca is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type-C disease.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Veanibek (previously Miglustat Gen.Orph) Authorised · Gen.Orph
- 🇪🇺 Miglustat Dipharma Authorised · Dipharma Arzneimittel GmbH
- 🇪🇺 Yargesa Authorised · Piramal Critical Care B.V.
- 🇪🇺 Miglustat Gen.Orph Authorised · Gen.Orph
- 🇪🇺 Opfolda Authorised · Amicus Therapeutics Europe Limited
Follow Zavesca
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.